Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 22Unknown 3Terminated 3Withdrawn 2

Sponsor Class

NIH 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Estramustine × Clear all
NCT00003066 2014-01-06

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT00003717 2013-12-19

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT00218205 2005-09-22

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Department of Veterans Affairs, New Jersey

Phase 2 Unknown
28 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡